12th-14th September, 2016


Day One
Tuesday 13th September 2016

Day Two
Wednesday 14th September 2016

Breakfast & Networking

Chairman’s Opening Remarks

Making the Translational Leap Between Pre-Clinical & Clinical

Alzheimer’s Disease Therapeutics: Possibilities & Pitfalls

  • Eric Karran Vice President, Distinguished Research Fellow, Foundational Neuroscience Center, AbbVie


  • Addressing the amyloid cascade hypothesis, its influence in both academic and industrial research and the resulting number of drugs that have reached clinical testing in man
  • Exploring the reasons behind why none of these drugs have met their primary outcome measures
  • Reviewing the prospects of drugs currently in clinical testing

Why Biomarkers are Key Prior to Pivotal Trials to Guide Dose & Efficacy in AD Patients

  • Birgitte Søgaard Divisional Director, Clinical & Quantitative Pharmacology, Lundbeck


  • Examining issues related to biomarkers guiding the dose
  • Evaluating the consequences of having the wrong biomarkers
  • Exploring the consequences of different biomarkers across the AD field

Back-Translation of Cortical EEG Biomarkers from Humans to Mice for Drug Discovery in Alzheimer’s Disease: The PharmaCog Project Way

  • Claudio Babiloni Associate Professor of Physiology, University of Rome “La Sapienza”


  • Testing translational values of electroencephalographic (EEG) and
  • other biomarkers in Alzheimer’s disease
  • Examining markers of on-going cortical EEG rhythms that reflect
  • prodromal AD processes in amnesic mild cognitive impairment
  • subjects
  • Observing analogous abnormalities in the EEG markers in transgenic
  • mouse models of AD
  • Discussing a translational value of EEG markers for an early evaluation of AD modifying drugs

Morning Refreshments

Driving Success in the Clinical Neurodegenerative Landscape

Maximising the Translatability of Early Development Proof of Principle Trials

  • Johan Luthman Vice President, Neuroscience Clinical Development, Eisai


  • Understanding how to design and execute translational PoP trials
  • Improving PoP endpoints to provide the most valuable data to inform the potential success of later phases
  • How to best translate pre-clinical research into early stage PoP studies to reliably reproduce drug effect

Harnessing Big Data & Wearable Technology to Advise Clinical Readouts

  • Carsten Spannhuth Global Program Medical Director & Digital Development Medical Adviser, Novartis


  • Examining wearable devices for frequent phenotyping of patients to support surrogate biomarker studies
  • Understanding what is the most meaningful data to discern changes in disease progression
  • How to utilise wearable tech data measures to show modification in cognition and function
  • Debating whether or not wearable tech can ultimately replace surrogate biomarkers
  • Does big data provide as much indication of disease modification as imaging data and biomarker tracking?
  • Addressing the regulatory requirements for the increased use of wearable tech in neuroscience clinical studies

Panel Discussion: Addressing the Clinical Trial Landscape

  • Carsten Spannhuth Global Program Medical Director & Digital Development Medical Adviser, Novartis
  • Johan Luthman Vice President, Neuroscience Clinical Development, Eisai
  • Robert O’Donnell Vice President, Global Regulatory Head, Johnson & Johnson


  • Are wearable devices the way forward and can they aid surrogate biomarker studies?
  • How can we best use negative trial data to drive clinical success?
  • How do you translate early phase markers of engagement into more meaningful studies?
  • What make the best clinical endpoints?
  • What do we really need to make a trial successful?
  • How many studies do we need in order to validate the prevention of disease development?
  • Addressing regulatory challenges and requirements for neurodegenerative drug candidates
  • Debating the reimbursement paradigm for neurodegenerative disease-modifying therapies

Networking Lunch

Next Generation Therapeutic Approaches for Targeting Neurodegenerative Diseases

Targeting the Spread of Pathology in Neurodegenerative Diseases


  • Elucidating biological triggers in the spread of neurodegeneration
  • Advancing modelling of pathological spread to identify viable therapeutic targets
  • Identifying novel strategies for targeting the spread of pathology to block the progression of neurodegeneration

The Precision Medicine Paradigm in Neurodegenerative Diseases

  • Harald Hampel Professor, AXA Research Fund & UPMC Chair, Sorbonne Universities, Pierre & Marie Curie University


  • Translating and facilitating the precision medicine paradigm in the neurodegeneration field area
  • Analysing advances in genetic methodologies and their impact in neurodegenerative research: Whole genome sequencing, whole exome sequencing and their application in systems biology
  • Understanding how precision medicine can inform translational drug discovery and development in neuroscience

Afternoon Refreshments

From the Bench to the Bedside: Exploiting Targets for Therapeutic Intervention in Neurodegeneration

  • Tiago Outeiro Professor & Director, Department of Neurodegeneration and Neurorestoration, University Medical Center Gottingen


  • Addressing protein misfolding as a common hallmark in neurodegeneration
  • Analysing protein aggregation: Innocent bystander or culprit?
  • Discussing novel molecular players in neurodegeneration
  • Making the leap from mechanism to therapies

Opportunities & Challenges in the Biotech World


  • Identifying what’s needed in order to provide sufficient evidence of drug efficacy and safety to advance through the developmental pipeline
  • Overcoming pre-clinical resourcing issues
  • Identifying valuable markers to advance drug discovery and development

Chairman’s Closing Remarks

Close of Day Two & End of Conference